BE prices Corbevax at Rs 145 for Government, Rs 800 for private players
Hyderabad: Hyderabad-based vaccine maker Biological E Limited (BE) has priced its Corbevax, which has got approval for administration to adolescents aged 12 to 14 years, at Rs 800 (excluding GST) per dose for the private market, and Rs 145 per dose for the government, making it the cheapest vaccine in India and also globally, the […]
Updated On - 16 March 2022, 08:41 PM
Hyderabad: Hyderabad-based vaccine maker Biological E Limited (BE) has priced its Corbevax, which has got approval for administration to adolescents aged 12 to 14 years, at Rs 800 (excluding GST) per dose for the private market, and Rs 145 per dose for the government, making it the cheapest vaccine in India and also globally, the company said.
Speaking to the media, Biological E Managing Director Mahima Datla said the company, which currently has about 30 crore Corbevax doses ready, has geared up to facilitate the first phase of vaccination drive for children.
The company collaborated with the Texas Children’s Hospital and the Baylor College to develop Corbevax, a recombinant protein subunit vaccine against the novel coronavirus. Multiple facilities in Hyderabad are currently producing the vaccine. It will partner with State governments, hospitals and medical institutions for supply of the vaccine, she said.
The vaccine will allow children to resume their in-person academic activities and also lower the concerns of parents. “Biological E has been strengthening its production and supply chain facilities to ensure efficient and fast administration of vaccines. We achieved a capacity to produce 100 million doses per month to ensure adequate supply and we are able to respond to any increasing demand,” she said.
The pricing of Corbevax in the private market will be Rs 990 inclusive of taxes and vaccine administration charges. BE develops, manufactures and supplies vaccines and therapeutics. Its products are sold in 130 countries and its therapeutic products are sold in India and the USA, Europe. BE currently has eight WHO-prequalified vaccines in its portfolio and five USFDA approved injectibles.
Now you can get handpicked stories from Telangana Today on Telegram everyday. Click the link to subscribe.
Click to follow Telangana Today Facebook page and Twitter .